Related Experiment Video
Updated: Jan 23, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center
Patrick Yau1, Victor H Jimenez-Zepeda2, Kyla Bailey1
1Department of Pharmacy, Tom Baker Cancer Center, Calgary, AB, Canada.
Abstract:
Lenalidomide is an immunomodulatory agent that belongs to a family of IMiDs used to treat multiple myeloma. Hypersensitivity and skin reactions are adverse effects of lenalidomide that may lead to discontinuation of its use for multiple myeloma making them contraindicated to other IMiD therapies. Desensitization protocols have been developed to desensitize patients to lenalidomide skin reaction and rash. We report a case series of 5 patients undergoing slow lenalidomide desensitization protocol in an outpatient cancer center setting. Four of the five patients were able to be successfully desensitized to lenalidomide. We also demonstrate safety of using slow lenalidomide desensitization while on combination therapy for control of multiple myeloma.
Related Concept Videos
Molecules with Multiple Chiral Centers
Patient-centered Care
GPCR Desensitization
Desensitization and Tachyphylaxis
Gene Evolution - Fast or Slow?
In contrast, regions which code...
Gene Evolution - Fast or Slow?

